Otsuka takes Asian rights to Ariad's Iclusig

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) licensed rights in 10 Asian territories to Iclusig ponatinib from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) to treat resistant and intolerant chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL).

Ariad will receive $77.5 million up front and is eligible for a milestone for Japanese approval to treat patients with resistant and intolerant Ph+ leukemias, plus other unspecified milestones and royalties. Otsuka gains exclusive rights to Iclusig in Japan, China, South Korea, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam. ...